Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

AmCad BioMed Corporation (4188.TWO)

Taipei Exchange - Taipei Exchange Delayed Price. Currency in TWD
Add to watchlist
17.900.00 (0.00%)
As of 12:26PM CST. Market open.
Advertisement

AmCad BioMed Corporation

No. 167 Fuxing North Road
3rd Floor Zhongshan District
Taipei 104
Taiwan
886 2 2713 6227
http://amcad.com.tw

Sector(s)Healthcare
IndustryMedical Devices
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Ms. Yi-Li LiExec. Director146kN/AN/A
Weitang HongFin. Mang. and Director45kN/AN/A
Ms. Yi-Li LeeDeputy Chairperson & PresN/AN/AN/A
Chih Yuan HuangFinancial & Accounting OfficerN/AN/AN/A
Mr. Zhenggang ChenChief R&D OfficerN/AN/AN/A
Amounts are as of December 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in TWD.

Description

AmCad BioMed Corporation develops computer-assisted detection and diagnosis (CAD) software devices primarily in Taiwan. Its products include AmCAD-UT Detection, a CAD device for ultrasound images of thyroid nodules; and AmCAD-UO, a solution for obstructive sleep apnea detection. The company is also developing AmCAD-CA, a software designed for analyzing digital cytological images; AmCAD-US, a software device for visualizing and quantifying statistical distributions of backscattered signals echoed by tissue compositions in the body from FDA-cleared ultrasound systems; and AmCAD-UV, a software device that is used for quantifying and classifying the ultrasonic color intensity data acquired from FDA-cleared ultrasound systems and displaying the noise-reduced color-coded pulsatile signals. The company was founded in 2008 and is based in Taipei City, Taiwan.

Corporate Governance

AmCad BioMed Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement